Magazine Article | June 1, 2022

Outsourcing Differences By Company Size — Biologic Drug Substance Manufacturing

Source: Life Science Leader

By Kate Hammeke, VP of Market Research, Industry Standard Research (ISR) @ISRreports

The maturation of the outsourcing industry comes with various benefits, a notable one being the removal of the multimillion- dollar financial barrier of in-house manufacturing for new and emerging companies. Virtual biopharmas are able to use CDMOs to further their discoveries through access to state-of-the-art manufacturing facilities, regulatory knowledge, and scientific expertise not possessed in-house. The proliferation of startup biopharmas over the past couple of decades will certainly speed up the pace of new medicines coming to market and hopefully improve and extend the lives of patients in the process.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: